TrialsgrambetaRCTs are beautiful

2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke

This guideline cites 9 of the 61 landmark trials in our Emergency medicine register.

Published on 26 January 2026, this guideline replaces the 2018 AHA/ASA acute ischaemic stroke guideline and its 2019 update, covering the whole early pathway — prehospital triage and mobile stroke units, imaging, thrombolysis, endovascular thrombectomy, early complication management and the start of secondary prevention. The main shifts are a broader role for tenecteplase within 4.5 hours, wider eligibility for thrombectomy (including basilar occlusion and large ischaemic cores), a rewritten list of thrombolysis contraindications, and the first dedicated recommendations for paediatric stroke. This page groups the register's reperfusion trials by the theme they inform.

Intravenous thrombolysis2

  • 2008ECASS III Core⁠Emergency · Stroke · IV thrombolysisIn 821 patients with acute ischaemic stroke 3–4.5 h from onset, alteplase improved mRS 0–1 at 90 days versus placebo.OR 1.3495% CI 1.02-1.76Read →
  • 1995NINDS rt-PA Core⁠Emergency · Stroke · IV thrombolysisIn 624 patients with acute ischaemic stroke within 3 h, intravenous alteplase 0.9 mg/kg improved functional outcome at 3 months versus placebo.OR 1.795% CI 1.2-2.6Read →

Imaging-guided selection & unknown-onset stroke1

  • 2018WAKE-UP⁠Emergency · Stroke · MRI-guided lysisIn 503 patients with ischaemic stroke of unknown onset and DWI–FLAIR mismatch, alteplase improved mRS 0–1 at 90 days versus placebo.OR 1.6195% CI 1.09-2.36Read →

Tenecteplase & choice of thrombolytic1

  • 2018EXTEND-IA TNK⁠Emergency · Stroke · TenecteplaseIn 202 patients with LVO before thrombectomy within 4.5 h, tenecteplase 0.25 mg/kg improved pre-thrombectomy reperfusion versus alteplase 0.9 mg/kg.22% vs 10%Read →

Endovascular thrombectomy: early window1

  • 2015MR CLEAN Core⁠Emergency · Stroke · ThrombectomyIn 500 patients with proximal anterior-circulation occlusion within 6 h, intra-arterial thrombectomy + standard care improved the 90-day mRS distribution versus standard care alone.OR 1.6795% CI 1.21-2.30Read →

Late-window, perfusion-selected thrombectomy2

  • 2018DAWN Core⁠Emergency · Stroke · Late-window thrombectomyIn 206 patients with LVO stroke 6–24 h from last known well, thrombectomy + standard care improved functional independence at 90 days versus standard care.49% vs 13%Read →
  • 2018DEFUSE 3 Core⁠Emergency · Stroke · Late-window thrombectomyIn 182 patients with anterior-circulation LVO 6–16 h, small core and perfusion mismatch, thrombectomy improved functional outcome at 90 days versus medical management.OR 2.7795% CI 1.63-4.70Read →

Large-core thrombectomy2

  • 2023SELECT2⁠Emergency · Stroke · Large-core thrombectomyIn 352 patients with large ischaemic core (ASPECTS 3–5 or core ≥ 50 mL), endovascular thrombectomy improved the 90-day mRS distribution versus medical management.OR 1.5195% CI 1.20-1.89Read →
  • 2023ANGEL-ASPECT⁠Emergency · Stroke · Large-core thrombectomyIn 456 Chinese patients with LVO and large ischaemic core, endovascular therapy improved the 90-day mRS distribution versus medical management.OR 1.3795% CI 1.11-1.69Read →

Cited landmark trials not yet in the register6

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2015ESCAPE / EXTEND-IA / SWIFT PRIME / REVASCAT

    The 2015 thrombectomy quartet that, with MR CLEAN, formed the HERMES pooled analysis.

  • 2012IST-3

    Alteplase up to 6 hours in a broad, largely elderly population.

  • 2019EXTEND

    Perfusion-imaging-selected thrombolysis in the 4.5–9-hour window.

  • 2022AcT

    Tenecteplase non-inferior to alteplase in routine practice — a pillar of the 2026 tenecteplase recommendation.

  • 2022ATTENTION / BAOCHE

    Thrombectomy for basilar-artery occlusion — the basis for the new posterior-circulation recommendation.

  • 2018CHANCE / POINT

    Short-course dual antiplatelet therapy after minor stroke or high-risk TIA.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.